Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
暂无分享,去创建一个
Wei Chen | Michael E Phelps | Albert Lai | James Sayre | Nagichettiar Satyamurthy | Johannes Czernin | T. Cloughesy | N. Satyamurthy | M. Phelps | Wei Chen | J. Sayre | J. Czernin | W. Pope | A. Lai | D. Silverman | C. Geist | Timothy Cloughesy | S. Delaloye | Sibylle Delaloye | Daniel H S Silverman | Cheri Geist | Whitney Pope | Cheri L. Geist
[1] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[2] P. Loehrer,et al. Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301 , 2007 .
[3] T. Manabe,et al. Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations , 2006, Clinical nuclear medicine.
[4] T. Mattfeldt,et al. Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.
[5] T. Turkington,et al. 3′-Deoxy-3′-[F-18]Fluorothymidine Positron Emission Tomography in Patients with Recurrent Glioblastoma Multiforme: Comparison with Gd-DTPA Enhanced Magnetic Resonance Imaging , 2006, Molecular Imaging and Biology.
[6] Qiulian Wu,et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.
[7] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[8] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[9] Ucla Medical. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006 .
[10] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[11] Karl Herholz,et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] Ricky T. Tong,et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] N. Di Lorenzo,et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines , 2005, British Journal of Cancer.
[14] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[15] R. Gray,et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .
[16] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] James H Thrall,et al. Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.
[19] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[20] Jae Seung Kim,et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[21] R. Ignoffo. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[22] M. Muzi,et al. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. , 2004, Nuclear medicine and biology.
[23] R. Kerbel,et al. Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development , 2004, Clinical Cancer Research.
[24] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[25] Mark Muzi,et al. Positron emission tomography imaging of brain tumors. , 2003, Neuroimaging clinics of North America.
[26] D. Visvikis,et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography , 2003, Gut.
[27] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] Sven N Reske,et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.
[29] A. Buck,et al. Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease , 2003 .
[30] Mark Muzi,et al. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] L. Wiens,et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] Y. Yonekura,et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.
[33] H. Machulla,et al. Synthesis and labeling of 5'-O-(4,4'-dimethoxytrityl)-2,3'-anhydr othymidine for [18F]FLT preparation , 2002 .
[34] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[35] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[36] M Schwaiger,et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[38] B. Drayer,et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.
[39] J. Slattery,et al. Chemotherapy response criteria in malignant glioma , 1997, Neurology.
[40] David Machin,et al. Sample Size Tables for Clinical Studies , 1997 .
[41] O. Witte,et al. Radiation necrosis or recurrence. , 1996, Journal of neurosurgery.
[42] R L Wahl,et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.
[43] W. Olivero,et al. The use of PET in evaluating patients with primary brain tumours: is it useful? , 1995, Journal of neurology, neurosurgery, and psychiatry.
[44] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[45] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Abass Alavi,et al. Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.
[47] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[48] D.,et al. Regression Models and Life-Tables , 2022 .